Skip to main content

Table 6 Outcomes after SIT

From: Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

Characteristics

Failed steroid tapering after SIT

IMC recurrence

OR (95% CI)

P

OR (95% CI)

P

ICI type

Anti-PD-1/L1 monotherapy

Reference

 

Reference

 

Anti-CTLA-4 therapy

0.50 (0.19–1.29)

0.150

1.09 (0.36–3.37)

0.871

Colitis grade

1–2

Reference

 

Reference

 

3–4

4.09 (1.53–10.98)

0.005

1.79 (0.59–3.38)

0.299

Multiple hospitalizations

9.05 (2.79–29.33)

< 0.001

26.25 (3.22–213.82)

0.002

Failed steroid tapering before SIT

3.75 (1.39–10.16)

0.009

2.42 (0.75–7.77)

0.138

Failed steroid tapering after SIT

4.07 (1.29–12.88)

0.017

Type of SIT

Vedolizumab

Reference

 

Reference

 

Infliximab

0.47 (0.18–1.22)

0.120

12.57 (1.57–100.57)

0.017

No. of SIT infusions

1–2

Reference

 

Reference

 

≥3

2.97 (1.13–7.79)

0.027

0.09 (0.01–0.72)

0.023

Endoscopic remission

1.68 (0.41–6.96)

0.474

0.15 (0.03–0.79)

0.025

Histologic remission

0.67 (0.18–2.46)

0.543

0.18 (0.04–0.88)

0.033

Number of steroids tapering attempts

9.50 (3.76–24.01)

< 0.001

3.35 (1.68–6.69)

0.001

Duration from IMC onset to SIT

1.05 (1.01–1.09)

0.011

1.00 (0.98–1.03)

0.774

Overall duration of steroids

1.02 (1.01–1.04)

0.001

1.01 (1.00–1.03)

0.022

Calprotectin at time of onset

1.00 (0.99–1.00)

0.599

1.00 (0.99–1.01)

0.346

Calprotectin after SIT

1.00 (0.99–1.00)

0.573

1.01 (1.00–1.01)

0.014

Duration of hospitalization

1.12 (1.04–1.21)

0.004

1.14 (1.05–1.23)

0.001

Duration of symptoms

1.06 (1.03–1.08)

< 0.001

1.02 (1.01–1.03)

0.008

  1. Abbreviations: CI, confidence interval; CTLA, cytotoxic T lymphocyte associated protein; SIT, selective immunosuppressive therapy; OR, odds ratio; PD-1, programmed death protein 1; PD-L1, PD-1 ligand